Cycling alpha cells in regenerative drug-treated human pancreatic islets may serve as key beta cell progenitors

Area of Science:

• Endocrinology
• Cell Biology
• Regenerative Medicine

Background:

• Diabetes mellitus is characterized by insufficient insulin-producing beta cells.
• Current treatments lack effective methods to restore beta cell mass.

Purpose of the Study:

• To elucidate the mechanisms by which DYRK1A inhibitors, alone or with GLP-1 receptor agonists or TGF-β inhibitors, increase beta cell mass.
• To identify responsive cell types and cellular pathways involved in beta cell regeneration.

Main Methods:

• Single-cell RNA sequencing of human pancreatic islets.
• Treatment with DYRK1A inhibitors, GLP-1 receptor agonists, and TGF-β superfamily inhibitors.
• Lineage trajectory and cell cycling analyses.

Main Results:

• DYRK1A inhibition primarily targets cycling alpha cells in human islets.
• Cycling alpha cells show potential as precursor cells for beta cell transdifferentiation.
• Regenerative drugs may enhance beta cell function and mass by targeting alpha cells.

Conclusions:

• Cycling alpha cells are a key target for regenerative therapies in diabetes.
• Transdifferentiation of alpha cells into beta cells is a potential mechanism for restoring beta cell mass.
• Findings provide insights into novel therapeutic strategies for diabetes treatment.